Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Mononitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | BCHE | P06276 | 6/20 | 0.55 |
| ▸ | GSR | P00390 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Mononitrate SCHEMBL8893344 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL5482432 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL616518 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL12238510 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8894719 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL23906861 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL12787633 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL26782 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL22067709 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8893635 | 0.96 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-10946197-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2021-03-16 | — | — | US | disclosed |
| US-10702533-B2 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2020-07-07 | — | — | US | disclosed |
| US-10086071-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170128457-A1 | Treatment of Conditions Through Pharmacological Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2017-05-11 | — | — | US | disclosed |
| US-9585851-B2 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160367807-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2016-12-22 | — | — | US | disclosed |
| US-20140086872-A1 | Methods of Treating a Subject for a Condition | PALO ALTO INVESTORS (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120270876-A1 | Treatment of Conditions Through Pharmacological Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2012-10-25 | — | — | US | disclosed |
| US-20110256097-A1 | Treatment of Conditions that Increase in Severity and/or Occurrence During One or More Phases of the Menstrual Cycle | PALO ALTO INVESTORS | 2011-10-20 | — | — | US | disclosed |
| US-7899527-B2 | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase | PALO ALTO INVESTORS (US) | 2011-03-01 | — | — | US | disclosed |
| US-20110015188-A1 | Treatment of Seasonal Conditions | PALO ALTO INVENTORS | 2011-01-20 | — | — | US | disclosed |
| US-20100286734-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2010-11-11 | — | — | US | disclosed |
| US-20100260669-A1 | Treatment of Seasonal Conditions Through Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2010-10-14 | — | — | US | disclosed |
| US-7738952-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100119482-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase | PALO ALTO INVESTORS | 2010-05-13 | — | — | US | disclosed |
| US-20050256028-A1 | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase | PALO ALTO INVESTORS | 2005-11-17 | — | — | US | disclosed |
| US-20050240241-A1 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-10-27 | — | — | US | disclosed |
| US-20050153885-A1 | administering aldosterone antagonists such as spironolactone and eplerenone, to increasing the parasympathetic and sympathetic activity | PALO ALTO INVESTORS | 2005-07-14 | — | — | US | disclosed |
| US-20050143378-A1 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-06-30 | — | — | US | disclosed |